Pursue pneumococcal vaccination policies vigorously


    loading  Checking for direct PDF access through Ovid

Abstract

IN BRIEFEvery effort should be made to increase immunisation rates among patients at high risk of pneumococcal disease or its complications, including the elderly.Pneumococcal capsular polysaccharide vaccine prevents pneumococcal disease in patients aged >2 years, although there is some evidence that its protective efficacy is reduced in immunocompromised patients. The incidence of adverse events related to vaccination appears to be low.The advent of protein-conjugated pneumococcal vaccines that are immunogenic in infants aged <2 years is eagerly anticipated, and may further reduce the burden of pneumococcal disease.

    loading  Loading Related Articles